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Abstract
The aim of this study was to analyze prostate 
cancer mortality and time trends in Brazil, ac-
cording to major geographic regions, States, and 
age brackets. Data on deaths from 1980 to 2010 
were obtained from the Mortality Information 
System. Mortality trends were estimated using 
Prais-Winsten generalized linear regression. 
An upward time trend was observed in mortal-
ity in all regions of Brazil, with a mean annual 
increase of 2.8%. The upward trend in mortal-
ity occurred in most of the age brackets, with a 
concentration of deaths in men 70 to 79 years of 
age (41%) and a significant increase in the 40 to 
60-year age bracket. The mortality rate increased 
significantly in all age brackets in the North-
east, compared to the other regions of Brazil. The 
study highlighted the importance of redistrib-
uting deaths from ill-defined causes in order to 
correct the mortality rates. The results point to 
significant regional differences and the need for 
continuous monitoring of mortality from pros-
tate cancer in Brazil.
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Resumo
Analisar a distribuição e a tendência temporal 
da mortalidade por câncer de próstata segun-
do macrorregiões, Unidades Federativas (UF) e 
faixa etária no Brasil. Foram utilizados dados 
do Sistema de Informações sobre Mortalidade 
(SIM), dos óbitos ocorridos entre 1980 e 2010. 
Estimou-se a tendência de mortalidade pelo 
método de Prais-Winsten de regressão linear 
generalizada. Verificou-se tendência temporal 
ascendente na taxa de mortalidade em todas as 
regiões do país, com aumento médio de 2,8% ao 
ano. A tendência ascendente na taxa de mortali-
dade ocorreu na maioria das faixas etárias, com 
concentração de óbitos entre homens de 70 a 79 
anos (41%) e aumento significativo entre 40 e 60 
anos. Houve um aumento significativo na taxa 
de mortalidade da Região Nordeste, e nas 25 UF 
em todas as faixas etárias comparada às demais 
regiões do Brasil. Verificou-se a importância na 
redistribuição de óbitos por causas mal defini-
das para correção das taxas de mortalidade. Os 
resultados apontam diferenças significativas re-
gionais e a necessidade de monitoramento con-
tínuo da mortalidade por câncer de próstata no 
Brasil.
Neoplasias da Próstata; Mortalidade; Saúde do 
Homem
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Introduction
Prostate cancer is the second leading tumor in in-
cidence and the sixth cause of death among men 
in the world 1. In Brazil, in the two years 2012 and 
2013 there were approximately 60,180 new cas-
es of prostate cancer, or an estimated risk of 62 
new cases per 100,000 men, ranking first among 
cancers in men, excluding skin cancer 2. In 20 
years, the crude mortality rate increased from 3.7 
deaths (1979) to 8.9 deaths per 100,000 (1990), 
ranking second as cause of death from cancer 
among men since 1999 3. The economic cost of 
detecting, treating, and monitoring prostate can-
cer is high, due to the aggregate costs, burdening 
the health system and individual patients and 
contributing to the families’ impoverishment 4. 
In the United States, in 2008, expenditures were 
nearly US$ 110,520 per patient 5.
Prostate cancer raises serious challenges for 
the development of preventive measures, given 
the lack of knowledge on its natural history, in 
addition to presenting a prolonged latency pe-
riod with multifocal and heterogeneous charac-
teristics 6.
The only well-established risk factor for pros-
tate cancer is age. Approximately 62% of cases 
in the world occur in men 65 years or older 2. In 
the United States, prostate cancer incidence in-
creased from 13.6 cases per 100,000 to 59.8 per 
100,000 in men under 65 years, and from 649.3 
to 763.4 cases per 100,000 in men over 65 years 
from 1975 to 2010 7. This difference has been at-
tributed to the increase in screening with digital 
rectal examination and prostate-specific antigen 
(PSA) screening in men 50 years and older 8.
Prostate cancer in individuals with a positive 
family history represents 13% to 26% of all cases. 
Epidemiological studies highlight that the risk of 
developing the disease among individuals with a 
family history is two to three times greater than 
expected for men of the same age bracket and 
ethnic group without a family history. Clinically, 
familial prostate cancer syndromes are diag-
nosed in 43% of patients less 70 years of age and 
9% of those over 85 years 9.
Research also suggests that race or ethnic-
ity is a risk factor for the disease, in addition to 
geographic region. Among African-descendant 
men in the United States, Jamaica, and other 
Caribbean countries, the risk of prostate cancer 
is 60% greater when compared to white Ameri-
cans, while for Asian-American men the risk is 
38% lower 9. This difference has been attributed 
to genetic susceptibility (5% to 10%) but also to 
heterogeneity in access to health services and 
different lifestyles between these groups. Diets 
with high animal fat and low intake of vitamins D 
and E, selenium, and isoflavonoids have been as-
sociated with increased risk of developing pros-
tate cancer 2,6.
Mortality rates from prostate cancer have de-
creased since 1990 in economically developed 
countries of North America and Europe and later 
in countries such as Chile, Argentina, Cuba, and 
Uruguay. Although this decline has been attrib-
uted to expansion in screening with PSA 10, there 
is no evidence of benefit from this measure for 
the majority of men without symptoms of the 
disease 11,12.
Studies in Brazil since the 1980s point to an 
upward trend in the mortality rate from pros-
tate cancer 13,14,15. The South and Southeast, the 
wealthiest and most economically developed re-
gions of the country, show a higher share of deaths 
from cancer when compared to the North and 
Northeast 13,15. In Recife, capital of Pernambuco 
State in Northeast Brazil, Oliveira Jr. & Cesse 16 
showed that although prostate was the second 
most common cancer site among men, since the 
risk was concentrated in the over-50 age bracket, 
its impact on years of potential life lost (YPLL) 
was the second lowest in 1990 and the lowest in 
1999 (with a 24.6% drop in that decade), suggest-
ing that deaths from prostate cancer were occur-
ring at older ages.
Few studies in Brazil have analyzed mortal-
ity trends from prostate cancer. Secondary mor-
tality data are available with 100% coverage and 
high national scope, thus allowing evaluations 
of trends in the disease itself and in health ser-
vices’ case-resolution capacity. However, there 
are important gaps in knowledge on differences 
in health services access, use, and performance, 
besides cultural and socioeconomic characteris-
tics related to lifestyle. These aspects appear to be 
reflected in annual variations in mortality rates 
from prostate cancer, with significant differences 
between the country’s major geographic regions 
in the last 31 years of coverage of the national 
Mortality Information System.
A literature review on prostate cancer mortal-
ity trends in PubMed, SciELO, and LILACS from 
June 2002 to June 2012 showed that the last such 
study in Brazil was published in 2011, referring 
to overall mortality trend from cancer, including 
prostate, from 1980 to 2006 17.
Considering the epidemiological relevance of 
prostate cancer in male morbidity and mortality, 
and since it shows good prognosis when detected 
in the early stages, on-going studies on its mor-
tality trends should be encouraged. The current 
study thus aimed to analyze the distribution and 
time trend in mortality from prostate cancer ac-
cording to the major geographic regions of Brazil.
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Methods
The study analyzed historical series of pros-
tate cancer mortality according to age bracket, 
States, and major geographic regions of Brazil 
from 1980 to 2010. Data on deaths (the numer-
ator in the mortality rate) were obtained from 
the Mortality Information System (Information 
Technology Department of the Brazilian Uni-
fied National Health System. http://www.da-
tasus.gov.br), including deaths from prostate 
cancer classified in the 9th and 10th revisions 
of the International Classification of Diseases 
(ICD-9 and ICD-10) with codes 185 (from 1980 
to 1995) and C61 (1996 to 2010) (Information 
Technology Department of the Brazilian Unified 
National Health System. Informações de Saúde: 
Demográficas e Socioeconômicas. http://www2.
datasus.gov.br/DATASUS/index.php?area=0206, 
accessed on 14/Feb/2012). Demographic data 
were population estimates (the denominator in 
mortality rates) provided by the Brazilian Insti-
tute of Geography and Statistics (IBGE. Popula-
ção Residente – Brasil, 2011. http://tabnet.data 
sus.gov.br/cgi/tabcgi.exe?ibge/cnv/popuf.def, 
accessed on 06/Dec/2011) for the respective 
years.
In order to minimize potential bias due to 
differences in data quality on death certificates 
between States and over the years, the percent-
age of deaths from ill-defined causes was redis-
tributed among other causes of death, except 
external causes 18.
Deaths from ill-defined causes with codes 
780-799 and R00-R99 in ICD-9 and ICD-10, re-
spectively, were redistributed proportionally ac-
cording to the methodology used by the World 
Health Organization (WHO) 19. This technique 
follows proportional redistribution by which 
coded deaths occur in each of the chapters of 
ICD-9 and ICD-10 among deaths from defined 
causes, except for external causes, and has been 
used in other Brazilian studies 18. Correction fac-
tors were calculated according to the following 
formula: correction factor = total deaths - deaths 
from external causes/total deaths - deaths from 
external causes - deaths from ill-defined causes.
To avoid overestimating the number of 
deaths from prostate cancer, we distributed 50% 
of the ill-defined causes as corresponding to neo-
plasms in each age bracket and State. This crite-
rion was based on Mello-Jorge et al. 20 for valida-
tion of ill-defined causes of death.
Deaths corrected by State and age bracket 
were totaled to comprise the data by major geo-
graphic region and Brazil as a whole. Mortality 
rates were calculated and standardized with and 
without correction, by age, using the direct meth-
od, taking the standard world population as the 
reference 21. Time trend analyses were performed 
according to major geographic regions (Central-
West, Northeast, North, Southeast, South) and 
age brackets (40-59, 60-69, 70-79, ≥ 80 years), and 
by State.
Time trend analysis used Prais-Winsten gen-
eralized linear regression 22, which allowed cor-
rection of first order autocorrelation in the analy-
sis of data organized over time. It was thus possi-
ble to interpret whether the mortality trends were 
increasing, decreasing, or stable, besides quanti-
fying the mean annual mortality increment with 
the respective 95% confidence intervals (95%CI). 
Statistical analysis used Stata version 9 (Stata 
Corp., College Station, USA).
To improve the visual grasp in the graphic 
display of time trends, third order moving aver-
age smoothing was used 22.
Results
From 1980 to 2010 there were 196,550 deaths from 
prostate cancer in Brazil, 49.7% in the Southeast 
region of the country and 20.6% in the Northeast. 
Redistribution of deaths from ill-defined causes 
led to a 7.7% increase, totaling 211,654 deaths. 
Standardized mortality rates increased from 9.9 
(unadjusted) to 10.8 deaths per 100,000 men 
after correction, for the period’s overall aver-
age. Risk of death from prostate cancer in Bra-
zil increased from 6.6 in 1980 to 14.2 deaths per 
100,000 men in 2010 (corrected rates) (Figure 1).
There was an upward trend in the mortality 
rate from prostate cancer in all major geograph-
ic regions of the country. The mortality rate in 
the Northeast increased from 3.8 in 1980 to 14.3 
deaths/100,000 men in 2010. In the South, the 
rate increased from 7.8 to 15.1 deaths, and in the 
Southeast from 6.9 to 14.3 deaths/100,000 men 
(Figure 2).
Table 1 shows the mean variation in mortality 
rates according to the major geographic regions 
and the country as a whole, and the respective 
prostate cancer mortality trends. The Northeast 
showed the highest mean annual variation with 
5%, while the lowest rates were in the South and 
Southeast, with mean annual increases of 2.4% 
and 2.6%, respectively. Although the risk of death 
increased in all the regions, the upward trend was 
smaller in the South and Southeast.
The highest mortality rates from 1980 to 2005 
occurred in the South and Southeast. For 18 and 
10 years, respectively, the States of Rio Grande 
do Sul and Rio de Janeiro maintained the high-
est mortality rates, although with downward time 
trends (data not shown).
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Figure 1
Historical series of mortality rates * from prostate cancer according to major geographic regions of Brazil from 1980 to 2010.
Figure 2
Prostate cancer mortality rate, uncorrected and corrected, in Brazil from 1980 to 2010.





















































































































































































The North showed the lowest rates from 1983 
(3.7 deaths per 100,000 men) to 2010 (10.1 deaths 
per 100,000 men) (data not shown).
Table 2 shows the trends in mortality rates in 
the five geographic regions according to the age 
bracket. The 70-and-older bracket concentrated 
41.4% of the deaths in the country. Of the total 
deaths, 6.5% occurred below 60 years of age.
Younger men (40 to 59 years of age) showed 
a stable mortality trend in the Central-West and 
South and an upward trend in the other regions. 
Comparing the 40-59 and 60-69-year age brack-
ets, the risk of dying increased 13 times in the 
country (from 3.0 to 39.7 deaths per 100 thou-
sand men). Mean variation in mortality rates was 
significantly higher in the Northeast compared 
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Table 1
Prostate cancer mortality trend, total corrected deaths, mean variation (% and 95% confidence interval – 95% CI), according  
to major geographic regions of Brazil, 1980 to 2010.
Regions Corrected deaths Mean variation (%) 95%CI Interpretation
Lower Upper
Central-West 12,189 3.5 2.9 4.1 Upward
Northeast 47,055 5.0 4.5 5.5 Upward
North 7,592 3.5 2.6 4.4 Upward
Southeast 105,089 2.6 2.0 3.2 Upward
South 39,730 2.4 1.8 3.1 Upward
Brazil 211,654 2.8 2.2 2.4 Upward
Table 2
Prostate cancer mortality trend and mean variation (% and 95% confidence interval – 95% CI) according to age brackets and major geographic regions of 
Brazil, 1980 to 2010.
Regions Mean variation [% (95%CI)] Interpretation
40-59 60-69 70-79 ≥ 80 40-59 60-69 70-79 ≥ 80
Central-West 1.4 (-0.1; 2.9) 2.4 (1.8; 3.1) 2.4 (1.8; 3.0) 3.2 (2.2; 4.2) Stable Upward Upward Upward
Northeast 2.1 (1.6; 2.6) 3.6 (2.9; 4.3) 4.2 (3.5; 4.9) 5.5 (4.6; 6.5) Upward Upward Upward Upward
North 1.5 (0.1; 2.9) 2.5 (2.0; 3.0) 3.1 (2.8; 3.5) 3.0 (1.9; 4.0) Upward Upward Upward Upward
Southeast 0.9 (0.2; 1.6) 0.9 (-0.1; 2.0) 0.9 (-0.2; 2.0) 1.9 (0.9; 2.9) Upward Stable Stable Upward
South 0.6 (-0.2; 1.4) 0.9 (0.0; 1.9) 1.6 (1.0; 2.3) 2.4 (1.4; 3.3) Stable Upward Upward Upward
Brazil 1.1 (0.5; 1.7) 1.5 (0.5; 2.4) 1.9 (1.2; 2.6) 2.9 (2.3; 3.5) Upward Upward Upward Upward
to the other regions of Brazil, in all age brackets 
(Table 2). 
Discussion
The study found an increase in mortality rates 
from prostate cancer in all regions of Brazil from 
1980 to 2010. The highest rates occurred in the 
South and Southeast. However, in the North and 
Northeast the mean annual increase was higher 
in the three decades. 
International time trend studies on mortality 
rates from prostate cancer identified decreases 
in England 23, France, Australia, United States 24, 
Singapore 25, Nordic countries 26, Austria 27, and 
Norway 28. Explanations for the downward trends 
in different countries suggest multiple factors, 
including changes in treatment strategies 24,28.
As in Brazil, countries like Russia, Japan, 24 
and Poland 29 presented upward mortality trends, 
suggesting natural aging 24 of the population as 
the principal trigger in cell alterations.
In the 1990s, the increase in prostate cancer 
incidence in all the Nordic countries except Den-
mark led to the suspicion that the mortality trend 
was overestimated. Older patients may have had 
prostate cancer recorded as their cause of death, 
while other causes such as heart failure and 
lung diseases may have been the real underlying 
causes of death 30.
A study that compared mortality from pros-
tate cancer in the United States and the United 
Kingdom showed that differences in treatment 
can help explain differences in mortality trends 
between countries. In the United States, prostate 
cancer patients receive more aggressive treat-
ment for the disease (radical prostatectomy) 
compared to the United Kingdom, where the 
mortality trend is higher. The drop in mortality 
in the United States may also be favored by the 
large number of trials involving new therapeutic 
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approaches (Information Technology Depart-
ment of the Brazilian Unified National Health 
System. IDB 2010 Brasil: Indicadores de Mor-
talidade, 2010. http://tabnet.datasus.gov.br/
cgi/tabcgi.exe?idb2010/c05.def, accessed on 04/
Sep/2012).
In Brazil, PSA tests paid for by the Brazilian 
Unified National Health System increased by 
573.3% (from 34,157 to 195,825) from 1999 to 
2007, with no indication of population and op-
portunistic screening by the Ministry of Health. 
The Southeast region supplied the most test, 
especially in the States of São Paulo and Minas 
Gerais (31.7% and 15%) 31, which may have con-
tributed to an increase in prostate cancer diag-
nosis. There was a 32.9% increase in diagnostic 
and therapeutic services from 2005 to 2009. From 
the regional perspective, the largest increases in 
services occurred in the Northeast (50.7%) and 
North (35%) and the lowest in the Central-West 
(15.2%) 32. However, the expansion of testing in 
the country had no impact in terms of a reduc-
tion in mortality.
The reduction in deaths from ill-defined 
causes and thus improvement in classification of 
causes of mortality for diseases in general in the 
Northeast and North can also be explained by 
the implementation of specific programs and ac-
tions at the Federal, State, and Municipal levels. 
In Brazil, the proportion of deaths from ill-de-
fined causes decreased from 20% in 1980 to 7.2% 
in 2009, when it varied from 3.8% in the Central 
West to 7.7% in the Northeast 33.
The increasing mortality rates in all States of 
the Northeast are also consistent with a study 
from 1996 to 2005, focusing on uterine cervical 
cancer 34. Improved access to diagnostic tests in 
the interior, leading to an increase in case detec-
tion, help explain this situation. Meanwhile, a 
study in Corumbá, Mato Grosso do Sul State 35, 
identified a downward trend in prostate cancer 
mortality, suggesting that improved diagnosis 
and treatment accounts for the drop in death 
from prostate cancer, corroborating other stud-
ies 23,24,25,26,27. According to a study from 1980 
to 2006, the increase in mortality rate was com-
mon to all the State capital cities in the major 
geographic regions, except the South of Brazil, 
where rates were higher in the countryside 16. 
According to the current study, the South and 
Southeast, Brazil’s wealthiest regions, showed the 
lowest mean annual increases, below average for 
the country. Quality of care, training in diagnosis 
and treatment, quality of information provided 
to patients, and increased survival for patients 
with a cancer diagnosis may have contributed to 
the differences in relation to the other regions of 
the country 36.
Analysis of mortality rates from prostate can-
cer by age bracket showed an upward trend in 
most of the regions. The exceptions, with stable 
mortality rates, included the Southeast (60 to 79 
years of age) and Central-West and South (40 to 59 
years), presumably due to intensification of early 
treatment, considering the increasing supply of 
radiotherapy services in these regions 17. Up-
ward trends in the other regions at ages above 70 
years corroborated the study by Fonseca et al. 14, 
which included prostate cancer in Brazilian State 
capitals.
Argentina showed an upward annual trend 
in prostate cancer mortality rates from 1986 to 
1998 in age brackets 55 to 64 years (1.3%), 65 to 
74 (3.6%), and 75 and older (4.4%), with a drop in 
subsequent years. The increase in deaths in older 
age brackets confirmed the striking effect of age, 
or the relationship between aging and mortal-
ity. The lower risk in younger age groups in this 
study suggests the influence of healthier behav-
ioral factors 37.
The current study showed a significant up-
ward trend in the mortality rate in the 40 to 
59-year age bracket, except in the Central-West 
and South of Brazil. In England and Wales, the 
mortality rate from prostate cancer declined by 
26% from 1992 to 2004 in the 55 to 74-year age 
bracket. The findings suggest greater use of radi-
cal prostatectomy to treat localized tumors, con-
tributing to a reduction in long-term mortality 
trends. In Brazil, there is still a gap in research on 
the association between the increase in deaths 
in the younger age bracket and family history 10.
Potential limitations to this study include 
the inability to disaggregate State mortality rates 
between the capital and the interior, in addition 
to the fact that the correction of deaths did not 
contemplate the imputation of unrecorded ages. 
However, in this study only 267 deaths (0.14%) 
presented unknown age.
The study increased the visibility and updat-
ed the situation with prostate cancer mortality in 
Brazil and its major geographic regions. Howev-
er, strategies are still needed to improve control 
measures for prostate cancer. The study high-
lights the importance of on-going improvement 
in data from information systems, indispensable 
for monitoring diseases.
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Resumen
Se analiza la distribución y la tendencia temporal de la 
mortalidad por cáncer de próstata según macrorregio-
nes, Unidades Federativas (UF) y franja etaria en Bra-
sil. Fueron utilizados datos del Sistema de Información 
sobre Mortalidad (SIM), con los óbitos acaecidos entre 
1980 y 2010. Se estimó la tendencia de mortalidad por 
el método de Prais-Winsten de regresión lineal genera-
lizado. Se verificó una tendencia temporal ascendente 
en la tasa de mortalidad en todas las regiones del país, 
con un aumento medio de un 2,8% al año. La tendencia 
ascendente en la tasa de mortalidad se produjo en la 
mayoría de las franjas de edad, concentrándose los óbi-
tos entre hombres de 70 a 79 años (41%) y un aumen-
to significativo entre 40 y 60 años. Hubo un aumento 
significativo en la tasa de mortalidad de la Región Nor-
deste, y en las 25 UF en todas las franjas de edad, com-
paradas con las demás regiones de Brasil. Se verificó la 
importancia en la redistribución de óbitos por causas 
mal definidas para la corrección de las tasas de morta-
lidad. Los resultados apuntan diferencias significativas 
regionales y la necesidad de un monitoreo continuo de 
la mortalidad por cáncer de próstata en Brasil.
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